Singapore markets open in 6 hours 41 minutes

Straits Times Index
3,415.51
+47.61(+1.41%)
S&P 500
5,537.02
+28.01(+0.51%)
Dow
39,308.00
-23.85(-0.06%)
Nasdaq
18,188.30
+159.54(+0.88%)
Bitcoin USD
60,295.55
-1,913.68(-3.08%)
CMC Crypto 200
1,296.70
-38.22(-2.86%)

PTCT Jul 2024 36.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.7500

0.0000

(0.00%)

At close: 12:08PM EDT

Zacks
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
PR Newswire
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the CHMP has issued a negative opinion on the renewal of the conditional marketing authorization of Translarna™ (ataluren) for the treatment of nmDMD. This opinion follows the return of the previously issued negative opinion by the European Commission (EC) for re-review.
Zacks
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.